Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has received U.S. Food and Drug Administration approval for its Investigational New Drug application for Lucid-MS (Lucid-21-302), clearing the way for the company to advance this first-in-class multiple sclerosis (MS) candidate into Phase 2 clinical development. The announcement, made on August 10, 2026, signals a pivotal milestone for the biopharmaceutical company, which has positioned Lucid-MS as a potential neuroprotective therapy that targets the underlying mechanism of demyelination rather than merely modulating the immune system.
The planned Phase 2 study will be a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS, using both clinical and radiological measures. According to the company, trial start-up activities, including site selection, are already underway, with patient enrollment and drug administration expected to begin as soon as possible. This rapid progression underscores the urgency to address the unmet medical needs in MS, where current treatments primarily focus on reducing immune-mediated attacks but do not directly prevent or reverse myelin damage.
Lucid-MS is designed to provide neuroprotection by inhibiting demyelination, differentiating it from existing MS therapies. The candidate targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. In preclinical models, Lucid-MS has demonstrated the ability to prevent and reverse myelin breakdown, offering hope for a disease-modifying therapy that could potentially restore function and slow disability progression. The company also reported that Lucid-MS demonstrated a favorable safety profile and was well tolerated in prior Phase 1 trials in healthy participants.
The FDA clearance is a critical step for Quantum BioPharma, which is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders. Lucid-MS is being developed through its wholly-owned subsidiary, Lucid Psycheceuticals Inc. The company's lead compound, Lucid-MS, is a patented new chemical entity that has shown promise in preclinical models for its ability to prevent and reverse myelin degradation, the underlying mechanism of MS.
In addition to the regulatory progress, Quantum BioPharma reported having more than $10 million in cash, digital assets, and liquid investments as of March 31, 2026, providing the financial runway to support the upcoming trial. The company also retains ownership of 19.84% of Unbuzzd Wellness Inc., and is entitled to royalty payments from sales of unbuzzd(TM) products, which could provide additional revenue streams in the future.
The approval of the IND application for Lucid-MS is a significant development for the MS community, as it brings a potential neuroprotective therapy one step closer to patients. If successful in Phase 2 and subsequent trials, Lucid-MS could offer a new approach to managing MS, potentially slowing or even reversing disability accumulation. The company plans to provide further updates as the trial progresses. For more information, visit the company's newsroom at https://ibn.fm/QNTM.
